Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Running

CHIRAL-MORPHS From Polymorphs of Racemic Compounds to Enantiopure Crystals

Coordinator
Stichting Nederlandse Wetenschappelijk Onderzoek Instituten, Netherlands
Runs
1 June 2026 to 30 November 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101293303

What the project is doing

In the project's own words, from its summary on CORDIS.

The molecular building blocks of life—such as sugars and amino acids—are of only one handedness. This broken molecular symmetry has important consequences for bioactive compounds: a molecule of one handedness can be an effective medicine while its mirror image is extremely toxic. Unfortunately, common chemical processes automatically yield both left- and right-handed molecules (i.e. enantiomers), and routes towards single handedness are often complicated, cumbersome, and costly.

Therefore, there is an urgent need for simple, scalable, sustainable, and economical routes to obtain enantiomerically pure molecules. Recently, we developed a radically new method to convert mixtures of both enantiomers into the desired form by exploiting crystallization. Our process already works on a variety of compounds and is exceptionally fast. However, to transform this fundamental breakthrough into a practical manufacturing method, we must broaden the range of compatible molecules, scale up and integrate the process, and establish a clear path to commercialization.

This ERC Proof-of-Concept project will validate both the technical feasibility and the commercial viability of our method. Commercially, we will conduct a systematic market analysis with trusted industrial partners, identify high-value pharmaceutical targets, and refine our intellectual-property and business strategy for licensing, contract research, or direct production. Using these steps, CHIRAL-MORPHS promises a cheaper, faster, and more sustainable path to enantiomerically pure building blocks.

If successful, it will remove a key bottleneck in the manufacture of chiral medicines, shorten drug-development timelines, and open broad opportunities across the pharmaceutical, agrochemical, and fine-chemical industries.

Who is involved

OrganisationCityCountryRole
Stichting Nederlandse Wetenschappelijk Onderzoek InstitutenUtrechtNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI